Abrégé

The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 9/51 - Nanocapsules
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester

Abrégé

Investigating the impact of BTG1 inactivation in lymphoma, the Inventors have demonstrated its role as a driver of lymphomagenesis in a murine model. They have also described the phenotypic consequences of BTG1 inactivation in human lymphoma cell lines. Especially, they have demonstrated that the inactivation of BTG1 is associated with an increased sensitivity to MCL-1 inhibition, which paves the way to the development of a personalized treatment for patients with BTG1 mutated lymphomas and cancers with a BTG1 inactivation. Accordingly, in a first aspect, the present invention relates to a method for predicting the response to a MCL-1 inhibitor treatment in a patient suffering from a cancer with a BTG1 inactivation, comprising the step of determining in a biological sample obtained from said patient the BTG1 mutation status, wherein a BTG1 inactivation is predictive of a response to a MCL-1 inhibitor treatment. In a second aspect, the present invention relates to a method of treating a patient suffering from a cancer with a BTG1 inactivation comprising the step of determining the BTG1 mutation status and administering a therapeutically effective amount of MCL-1 inhibitor when the patient carries a BTG1 gene inactivation.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

LdlrLdlrLdlr/" females; 2) potently decreases the size of aortic atherosclerotic lesions. These preliminary data support the hypothesis of a beneficial role of LIPC E97G towards the development of atherosclerosis and reinforce the need for further studies. Interestingly, they also open the prospect of new therapeutic solutions in familial hypercholesterolemia (EH) patients with partial/total EDER deficiency. The present invention relates to a method for treating hypercholesterolemia, including homozygous and heterozygous EH, and related ASCVD in a subject in need thereof comprising administering a therapeutically effective amount of a LIPC variant to said subject in need thereof.

Classes IPC  ?

• A61K 38/46 - Hydrolases (3)
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 3/06 - Antihyperlipémiants
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention relates to a method for removing uremic toxins bound to a protein from the blood of a patient in need thereof. The method comprises the introduction in the blood of a displacer substance chosen from (C6-C12)-fatty acids, salts of (C6-C12)-fatty acids, a precursor of said (C6-C12)-fatty acids, or mixtures thereof. The displacer substance replaces the uremic toxins bound to the protein, thereby releasing unbound uremic toxins in the blood. The unbound uremic toxins are then removed from the blood by any method of dialysis. The method according to the invention involves low concentrations of displacer substance and is effective at plasma concentrations comprised in the range of from 0.5 to 3 mM.

Classes IPC  ?

• A61M 1/16 - Systèmes de dialyseReins artificielsOxygénateurs du sang avec membranes
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61M 1/34 - Filtration du sang à travers une membrane pour en éliminer une matière, c.-à-d. hémofiltration, diafiltration
• A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p. ex. adaptation de la température, irradiation

Abrégé

The invention relates to a method for removing uremic toxins bound to a protein from the blood of a patient in need thereof. The method comprises the introduction in the blood of a displacer substance chosen from (C6-C12)-fatty acids, salts of (C6-C12)-fatty acids, a precursor of said (C6-C12)-fatty acids, or mixtures thereof. The displacer substance replaces the uremic toxins bound to the protein, thereby releasing unbound uremic toxins in the blood. The unbound uremic toxins are then removed from the blood by any method of dialysis. The method according to the invention involves low concentrations of displacer substance and is effective at plasma concentrations comprised in the range of from 1 µM to 3 mM.

Classes IPC  ?

• A61M 1/16 - Systèmes de dialyseReins artificielsOxygénateurs du sang avec membranes
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61M 1/34 - Filtration du sang à travers une membrane pour en éliminer une matière, c.-à-d. hémofiltration, diafiltration
• A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p. ex. adaptation de la température, irradiation
• A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
• A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique

Abrégé

The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.

Classes IPC  ?

• A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
• A61P 35/00 - Agents anticancéreux
• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance

Abrégé

A method for determining, in vitro or ex vivo, the presence in a patient of an infection by a replicating respiratory virus, including a step i) of determining, in a test sample taken from the mouth or nose of said patient, the level of transcripts of at least one marker gene selected from the interferon-stimulated genes, referred to as ISGs; and associated kits.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
• C12Q 1/6851 - Amplification quantitative

Abrégé

The invention provides a clonal cell line derived from a liver cancer cell line, preferably derived from a Huh7 hepatocarcinoma cell line, engineered to produce and secrete viral particles containing pregenomic RNA of the hepatitis B virus (HBV), predominantly over DNA of HBV, to calibrate quantitative HBV RNA assays.

Classes IPC  ?

• C12N 5/09 - Cellules tumorales
• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• C12R 1/91 - Lignées cellulaires

Abrégé

The invention relates to a method of determining, from an assayed sample or a population of assayed samples previously drawn from patients, a transcriptomic score (TScore) suitable for assessing a risk of adverse clinical outcome for patients in a clinical setting, said method involving, amongst other steps, the measurement of gene expression values on a patient sample or a population of samples previously obtained from patients for at least two distinct genes selected among a predetermined set of genes, and the determination of a transcriptomic score where the genes are assigned or not assigned a point. The method can be computer-implemented. The genes of the predetermined set of genes can be at least two genes selected among: ADGRE3, ARL14EP, BPGM, C3AR1, CCNB1IP1, CD177, CD274, CD3D, CD74, CIITA, CTLA4, CX3CR1, GNLY, IFNgamma, IL10, IL1R2, IL1RN, IL7R, IP10/CXCL10, MDC1, OAS2, S100A9, TAP2, TDRD9, TNF and ZAP70. The method can be implemented on assayed biological sample(s) drawn from patient(s) which have been admitted in a reanimation unit, an intensive or continuing care unit. The invention also relates to a method to classify a sample previously drawn from a patient, in a group reflecting a risk of adverse clinical outcome in a clinical setting, or to identify a patient at risk of adverse clinical outcome in a clinical setting, as well as an in vitro or ex vivo method of screening whether a drug has the capacity to alleviate an adverse clinical outcome in a patient. The invention also relates to computer means for implementing the invention, and the use of a kit for carrying out a method of the invention.

Classes IPC  ?

• C12Q 1/12 - Bactéries réduisant les nitrates en nitrites
• C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to a prosthesis (1) for a endobypass pending future anastomosis, having: a leaktight wall (2) forming a conduit between first and second orifices (25, 26) which are positioned at first and second segments (21, 22) of the leaktight wall; a first stent (31) encircling the leaktight wall (2) at the first segment; a second stent (32) encircling the leaktight wall at the second segment; the leaktight wall having an intermediate segment (23) arranged between the first and second segments and composed of first and second faces (231, 232) extending over respective angular portions; a third stent (33) integral with the first face of the intermediate segment (23) of the leaktight wall (2), the third stent extending over the entire angular portion of the first face (231), the second face (232) of the intermediate segment (23) being without a stent.

Classes IPC  ?

• A61F 2/06 - Vaisseaux sanguins
• A61F 2/07 - Endoprothèses déployables couvertes

Abrégé

A fenestrated endoprosthesis of the thoracic aorta including a first mesh of stents, a main tubular endoprosthesis made of fabric, the main tubular endoprosthesis being rigidly attached to the first mesh, and having an arcuate central portion configured to be received in the aortic arch of a patient, the arcuate central portion extending between a first and a second end, each configured to be received respectively in a portion of the ascending or descending aorta, respectively. The fenestrated endoprosthesis further includes a flange also made of fabric and associated with a second mesh of stents, the flange having a substantially frustoconical shape and having a base, the base of the flange being mounted on an opening made in the upper face of the arcuate central portion, the flange being configured to be received at the base of the supra-aortic trunks of the patient.

Classes IPC  ?

• A61F 2/07 - Endoprothèses déployables couvertes
• A61F 2/06 - Vaisseaux sanguins
• A61F 2/89 - Stents ayant une forme caractérisée par des éléments filiformesStents ayant une forme caractérisée par une structure de type filet ou de type à mailles les éléments filiformes comprenant au moins deux anneaux adjacents reliés de manière flexible par des éléments séparés

Abrégé

The invention relates to a system and a method for computer-aided detection (CAD) of aggressive prostate cancers. The automatic diagnosis of aggressive prostate cancers is difficult and methods that work with some MRI scanners do not work as well when implemented on images from different scanners. By studying a data base containing MRI data and biopsy results from 265 patients, acquired by 4 different types of MRI scanners, using machine learning techniques, the inventors established a method for automatically determining the presence of aggressive cancers, this methods showing high sensitivity and specificity when implemented on another database containing MRI data from 270 patients, acquired by different MRI scanners than the first database. The method involves feeding MRI images to a system calculating a score for a portion of the prostate and determines that the portion contains an aggressive cancer based on whether a criterion depending on the score is verified.

Classes IPC  ?

• G06T 7/00 - Analyse d'image

Abrégé

The present invention relates to a method for imaging an anatomical structure in a subject in need thereof, comprising the following steps: a) providing an injectable pharmaceutical composition comprising, as a contrast agent, at least one nanoparticle having a mean hydrodynamic diameter below 10 nm and comprising:. a biocompatible matrix, such as polyorganosiloxane,. at least one chelating agent covalently bonded to said biocompatible matrix,. at least one element having a Z of at least 40, chelated to at least a part of the chelating agents, b) injecting an effective amount of said pharmaceutical to said subject, and, c) acquiring an imaging scan of an anatomical structure of said subject in need thereof, by Spectral Photon Counting Computed Tomography (SPCCT) scanning.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo
• A61K 49/04 - Préparations de contraste pour rayons X
• A61K 49/08 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par le support
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 35/00 - Agents anticancéreux

Abrégé

This disclosure relates to a method for characterizing activation of an anatomical tissue subjected to contraction, aiming at providing a characterization of the contraction itself in a quantitative manner which is accurate and repeatable. The invention proposes an analysis of the activation of the anatomical structure based on instantaneous spectral contents of an activity signal from which an identification of peaks of dominant frequency characterizing the contraction throughout the anatomical tissue results. An evolution of a spatial distribution of peaks of dominant frequency throughout the anatomical tissue over time can also be monitored. The disclosure finds particular advantageous applications in provision of a mapping of activation of the anatomical tissue in order to identify a possible dysfunction, such as an arrhythmia in a cardiac tissue.

Classes IPC  ?

• A61B 5/367 - Études électrophysiologiques [EEP], p. ex. cartographie de l’activation électrique ou cartographie électroanatomique
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/346 - Analyse des électrocardiogrammes
• A61B 8/08 - Applications cliniques

Abrégé

The present invention relates to a method for in vitro or ex vivo detection of an immunocompromised status in a subject, comprising quantifying, in a biological sample of said subject, the expression of at least 2 target genes selected from the group consisting of TAP2, C3AR1, CD177 and IL1R2, and identifying whether or not a variation in their expression is present as compared to a reference value. The invention also relates to tools for implementing said method, and to uses thereof.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The subject matter is a method for determining the proliferation capacity of T lymphocytes in a subject, the method including the following steps: a) measuring the load of torque teno virus from a biological sample of the subject; and b) determining the proliferative capacity of the T lymphocytes based on the viral load measured in a).

Classes IPC  ?

• C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

in vitroex vivoex vivo method for determining the risk of death for a subject infected with a respiratory virus, said method comprising the steps of measuring, in a biological sample from said subject, the expression level of the OAS2 gene, and comparing the expression level thus measured or a value derived from this amount to a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death for the subject when a sub-expression of the OAS2 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of OAS2 can be supplemented by a measurement of one or more additional genes such as C3AR1, CD177, ADGRE3, CIITA, IL-10, IL1R2, CD74, TDRD9 and combinations thereof. Kits for measuring the expression of OAS2 and optionally one or more additional genes are also disclosed.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of death in a subject infected with a respiratory virus, for example SARS-CoV-2, comprising a measurement, in a biological sample of said subject, of the level of expression of the CD74 gene; the invention also relates to associated kits.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

The invention relates to an in vitro or ex vivo determination method for determining the risk of death of a patient infected by a respiratory virus, said method comprising the steps of measuring, in a biological sample from said patient, the expression level of the ADGRE3 gene, and of comparing the expression level thus measured or a value derived from this quantity with a predetermined reference value. The method thus makes it possible to conclude that there is an increased risk of death of the patient when an underexpression of the ADGRE3 gene is statistically demonstrated from the biological sample. Advantageously, the measurement of the expression level of ADGRE3 can be supplemented by the measurement of one or more additional genes such as C3AR1, CD177, OAS2, CIITA, IL-10, IL1R2, CD74, TDRD9 and combinations thereof. The invention also relates to kits for measuring the expression of ADGRE3 and optionally of one or more additional genes.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The present invention relates to a method for detecting an infectious transmission in a population, the method being characterised in that it comprises implementing, by data processing means (20) of a client (2), steps of: (b) for a plurality of infectious agent isolates, each associated with an individual of said population, obtaining a vector with values descriptive of the isolate; (c) for each pair of a first isolate (X) and a second isolate (Y) of the plurality, respectively associated with a first individual and a second individual of said population: (c1) calculating a first number of isolates (n(X)) corresponding to the number of isolates of said plurality having a distance to the first isolate (X) less than or equal to a reference distance between the first and second isolates (X, Y), and a second number of isolates (n(Y)) corresponding to the number of isolates of said plurality having a distance to the second isolate (Y) less than or equal to said reference distance between the first and second isolates (X, Y), each distance between two isolates being representative of a dissimilarity between the vectors of values descriptive of these two isolates; (c2) estimating a probability (TXY) of direct infectious transmission between the first and second individuals as a function of said first and second number of isolates (n(X), n(Y)); (d) detecting or not detecting an infectious transmission in said population as a function of the estimated probabilities (TXY) of direct infectious transition between each pair of individuals.

Classes IPC  ?

• G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
• G16H 70/60 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pathologies
• G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
• G16B 40/10 - Traitement du signal, p. ex. de spectrométrie de masse ou de réaction en chaîne par polymérase

Abrégé

In the present invention, inventors investigate the representation of T cell subsets in Toxic epidermal necrolysis (TEN) a life-threatening cutaneous adverse drug reaction (cADR), characterized by massive epidermal necrosis. To better understand why skin symptoms are so severe in TEN disease, inventors conducted a prospective immunophenotyping study on skin samples and blood from 18 TEN patients, using mass cytometry and next generation TCR sequencing. Deep sequencing of the T cell receptor CDR3 repertoire revealed massive expansion of unique CDR3 clonotypes in blister cells. Over-represented clonotypes were mainly effector memory CD8+CD45RA−CCR7− T cells, and expressed high levels of cytotoxic (Granulysin and Granzymes A & B) and activation (CD38) markers. Thus present invention relates to non-invasive, specific and rapid methods for diagnostic and monitoring Toxic Epidermal Necrolysis. More specifically present invention relates to methods for diagnosis and/or monitoring of Toxic Epidermal Necrolysis through detection of a specific population of T lymphocytes in a subject. The present invention also relates to a method of preventing or treating a Toxic Epidermal Necrolysis in a subject in need thereof.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoanitibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

Classes IPC  ?

• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 9/08 - Solutions
• A61P 35/00 - Agents anticancéreux
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules

Abrégé

The aim of the invention is to provide a traction device for sufficiently exposing the submucosa so as to provide suitable conditions for the dissection device to move freely throughout the entire dissection of the tumoral mucosa. The traction device (1) of the invention is characterised in that it comprises a proximal anchor (3) that is mounted so as to move relative to an elastic member (2) between a minimum proximal distance and a maximum proximal distance, and in that the traction device comprises an adjustment member (6) configured to adjust the maximum proximal distance between the initial maximum proximal distance and a final maximum proximal distance smaller than the initial maximum proximal distance.

Classes IPC  ?

• A61B 17/02 - Instruments, dispositifs ou procédés chirurgicaux pour maintenir les blessures ouvertes, p. ex. rétracteursÉcarteurs
• A61B 17/08 - Clamps pour blessures
• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
• A61B 17/32 - Instruments chirurgicaux coupants

Abrégé

in vitro in vitro method for determining whether a newborn patient has late-onset neonatal sepsis, which comprises determining the PTX-3 protein concentration in a biological sample previously obtained from said patient.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a process for identifying patients affected by an autoimmune neurological disease, comprising a step of detection of at least one type of anti-Argonaute autoantibodies (AGO-Abs) in a biological sample of an individual susceptible to be affected by said disease, wherein positive detection of said at least one type of AGO-Abs means that said individual is affected by said autoimmune neurological disease.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The Inventors have developed an ELISA of a new molecular marker detecting a neoepitope generated from the cleavage of the α1 chain of type III collagen within its helical domain. Serum levels of this marker were significantly increased in patients with RA and is significantly associated to CRP and ESR levels. Indeed, they demonstrated that the median serum HELIX-III levels were significantly higher in patients with moderate (p=0027) and active RA (p=00004) compared with those in age-matched controls. The present invention relates to an antibody recognizing an epitope having SEQ ID NO :1 of collagen protein and its uses for diagnostic, prognostic and monitoring purposes.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Staphylococcus aureusStaphylococcus aureusStaphylococcus aureusStaphylococcus aureus strain present in the biological sample.

Classes IPC  ?

• C12Q 1/14 - StreptocoquesStaphylocoques
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
• C12R 1/445 - Staphylococcus aureus

Abrégé

The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The invention relates to a nanoparticle comprising at least one cationic lipid, at least one neutral lipid, and at least one pH sensitive lipid which differs from said cationic lipid, which can be used as a vector for the transport and release of nucleic acids within cells.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

Abrégé

The invention relates to a positioning support (1) for positioning control pedals of medical-technical or surgical intervention tools, comprising: - an elongate link (2) provided with a plurality of attachment locations (200) distributed along the length thereof; - a plurality of attachment devices (3) for control pedals, each comprising a first interface (31) for fitting a control pedal, and a second interface (32) for securing to an attachment point (200) of the elongate link (2), the second securing interface (32) being configured so as to be able to be selectively secured to or detached from a point of the elongate link (2).

Classes IPC  ?

• A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux
• G05G 1/40 - Organes de commande actionnés par le pied réglables

Abrégé

The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.

Classes IPC  ?

• A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

Investigating the impact of BTG1 inactivation in lymphoma, the Inventors have demonstrated its role as a driver of lymphomagenesis in a murine model. They have also described the phenotypic consequences of BTG1 inactivation in human lymphoma cell lines. Especially, they have demonstrated that the inactivation of BTG1 is associated with an increased sensitivity to MCL-1 inhibition, which paves the way to the development of a personalized treatment for patients with BTG1 mutated lymphomas and cancers with a BTG1 inactivation. Accordingly, in a first aspect, the present invention relates to a method for predicting the response to a MCL-1 inhibitor treatment in a patient suffering from a cancer with a BTG1 inactivation, comprising the step of determining in a biological sample obtained from said patient the BTG1 mutation status, wherein a BTG1 inactivation is predictive of a response to a MCL-1 inhibitor treatment. In a second aspect, the present invention relates to a method of treating a patient suffering from a cancer with a BTG1 inactivation comprising the step of determining the BTG1 mutation status and administering a therapeutically effective amount of MCL-1 inhibitor when the patient carries a BTGI gene inactivation.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to benzimidazole derivatives and pharmaceutical compositions comprising such benzimidazole derivatives, for use in the treatment or prevention of a histiocytosis or a craniopharyngioma.

Classes IPC  ?

• A61K 31/4184 - 1,3-Diazoles condensés avec des carbocycles, p. ex. benzimidazoles
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 35/00 - Agents anticancéreux
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The invention relates to a prosthesis (1) for a bypass pending future anastomosis, having: - a leaktight wall (2) forming a conduit between first and second orifices (25, 26) which are positioned at first and second segments (21, 22) of the leaktight wall; - a first stent (31) encircling the leaktight wall (2) at the first segment; - a second stent (32) encircling the leaktight wall at the second segment; - the leaktight wall having an intermediate segment (23) arranged between the first and second segments and composed of first and second faces (231, 232) extending over respective angular portions; - a third stent (33) rigidly connected to the first face of the intermediate segment (23) of the leaktight wall (2), the third stent extending over the entire angular portion of the first face (231), the second face (232) of the intermediate segment (23) being without a stent.

Classes IPC  ?

• A61F 2/06 - Vaisseaux sanguins

Abrégé

The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments

Abrégé

The present invention is based on the finding that Netrin-(1) is retained in a stickier manner in the cell matrix at the cell periphery of the cancer cells, whereas Netrin-(1) is expressed in adults specifically in some tumors. It is also shown herein that Netrin-(1) is expressed very early during tumor formation. This makes Netrin-(1) an unexpected very specific target for imagery and/or targeted therapy. The present invention thus relates to compounds comprising an anti-Netrin-1 antibody, especially NP(137), a chelating moiety, optionally associated with a radioisotope, and their use either in imagery, diagnosis, especially companion diagnosis, or in targeted therapy. New diagnostic tests, which may be companion tests, and new cancer therapies, that may be combined to the companion test, are also proposed.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a method for in vitro or ex vivo assessment of the risk of complications in a patient admitted to a healthcare facility, the method comprising measuring the viral load of at least one torque teno virus (TTV) in a biological sample of said patient, characterised in that said patient is not undergoing immunosuppressive treatment.

Classes IPC  ?

• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The invention relates to a method for the identification of at least one microorganism present in a sample, based on the detection of peptides issued from the cleavage of ribosomal proteins of said microorganism, comprising the following steps: a) lysis of microorganism(s) and cleavage of the proteins present in said sample, to obtain a mixture of peptides, b) decomplexing said peptides mixture using a liquid separation device coupled with a mass spectrometer, c) nebulizing the liquid eluted from the separation device using an ion source, in order to produce an ion current, d) receiving said ion current from the ion source using said mass spectrometer and, for each cycle of a plurality of cycles, executing on the ion current a series of filtering steps for detecting a transition, said transition comprising a precursor ion and at least one fragment ion of said precursor ion, said transition being read from a predefined list of transitions using the mass spectrometer, wherein for each transition of the series, the mass spectrometer selects and fragments a precursor ion of the each transition; e) receiving data concerning a plurality of transitions to be used to monitor the mixture of peptides using the processor, f) assigning said plurality of transitions into two or more contiguous groups of transitions, into said predefined list of transitions, using the processor, g) monitoring at least one sentinel transition associated with one sentinel compound in each group of the two or more contiguous groups, wherein said at least one sentinel transition is selected as having the latest expected retention time in the group, using the processor, h) when the signal of at least one sentinel transition of a group is detected with the mass spectrometer, starting the monitoring of at least one sentinel transition in a next contiguous group while stopping the monitoring of the transitions of the preceding group, using the processor, i) optionally, generating a chromatogram or electropherogram, from the detection of transitions read from a predefined list with said mass spectrometer, using the processor, wherein each transition read from the predefined listed is associated to a peptide, and wherein the microorganism is identified according to the detection of said peptide(s).

Classes IPC  ?

• G01N 30/86 - Analyse des signaux
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a method for the identification of at least one microorganism present in a sample, based on the detection of peptides issued from the cleavage of ribosomal proteins of said microorganism, comprising the following steps: a) lysis of microorganism(s) and cleavage of the proteins present in said sample, to obtain a mixture of peptides, b) decomplexing said peptides mixture using a liquid separation device coupled with a mass spectrometer, c) nebulizing the liquid eluted from the separation device using an ion source, in order to produce an ion current, d) receiving said ion current from the ion source using said mass spectrometer and, for each cycle of a plurality of cycles, executing on the ion current a series of filtering steps for detecting a transition, said transition comprising a precursor ion and at least one fragment ion of said precursor ion, said transition being read from a predefined list of transitions using the mass spectrometer, wherein for each transition of the series, the mass spectrometer selects and fragments a precursor ion of the each transition; e) receiving data concerning a plurality of transitions to be used to monitor the mixture of peptides using the processor, f) assigning said plurality of transitions into two or more contiguous groups of transitions, into said predefined list of transitions, using the processor, g) monitoring at least one sentinel transition associated with one sentinel compound in each group of the two or more contiguous groups, wherein said at least one sentinel transition is selected as having the latest expected retention time in the group, using the processor, h) when the signal of at least one sentinel transition of a group is detected with the mass spectrometer, starting the monitoring of at least one sentinel transition in a next contiguous group while stopping the monitoring of the transitions of the preceding group, using the processor, i) optionally, generating a chromatogram or electropherogram, from the detection of transitions read from a predefined list with said mass spectrometer, using the processor, wherein each transition read from the predefined listed is associated to a peptide, and wherein the microorganism is identified according to the detection of said peptide(s).

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 30/86 - Analyse des signaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a method for determining, in vitro or ex vivo, the presence in a patient of an infection by a replicating respiratory virus, comprising a step i) of determining, in a test sample taken from the mouth or nose of said patient, the level of transcripts of at least one marker gene selected from the interferon-stimulated genes, referred to as ISGs. The invention also relates to the associated kits. Figure for the abstract: none.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

This disclosure relates to a method for characterizing activation of an anatomical tissue subjected to contraction, aiming at providing a characterization of the contraction itself in a quantitative manner which is accurate and repeatable. The invention proposes an analysis of the activation of the anatomical structure based on instantaneous spectral contents of an activity signal from which an identification of peaks of dominant frequency characterizing the contraction throughout the anatomical tissue results. An evolution of a spatial distribution of peaks of dominant frequency throughout the anatomical tissue over time can also be monitored. The disclosure finds particular advantageous applications in provision of a mapping of activation of the anatomical tissue in order to identify a possible dysfunction, such as an arrhythmia in a cardiac tissue.

Classes IPC  ?

• A61B 8/08 - Applications cliniques
• A61B 8/12 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores dans des cavités ou des conduits du corps, p. ex. en utilisant des cathéters
• A61B 5/367 - Études électrophysiologiques [EEP], p. ex. cartographie de l’activation électrique ou cartographie électroanatomique
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The invention relates to a fenestrated endoprosthesis of the thoracic aorta comprising a first mesh of stents (2), a main tubular endoprosthesis (1) made of fabric, the main tubular endoprosthesis being rigidly attached to the first mesh, and having an arcuate central portion (12) configured to be received in the aortic arch of a patient, the arcuate central portion extending between a first (10) and a second (11) end, each configured to be received respectively in a portion of the ascending or descending aorta, respectively, the fenestrated endoprosthesis further comprising a flange (3) also made of fabric and associated with a second mesh of stents (4), the flange having a substantially frustoconical shape and having a base (30), the base of the flange being mounted on an opening (13) made in the upper face of the arcuate central portion (12), the flange (3) being configured to be received at the base of the supra-aortic trunks of the patient.

Classes IPC  ?

• A61F 2/07 - Endoprothèses déployables couvertes

Abrégé

The invention relates a fluorescent compound of formula I: wherein A is selected from P, P═O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.

Classes IPC  ?

• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• C09B 57/00 - Autres colorants synthétiques de structure connue
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 21/64 - FluorescencePhosphorescence

Abrégé

The invention relates to an intervention device (9) for transcatheter cardiovascular surgery, comprising: - a cardiovascular ultrasound catheter (1) having a first elongate body (10) provided with a proximal end (11), said ultrasound catheter comprising an acoustic transducer (12) at its proximal end and a connection cable (13) extending within the first elongate body; - a surgical intervention tool (2) having a second elongate body (20), a surgical intervention head (21) positioned in proximity to the acoustic transducer (12) of the ultrasound catheter; - a guide catheter (4) having a sheath (40) in which the first and second elongate bodies are housed and rigidly connected, the surgical intervention head (21) and the acoustic transducer (12) protruding from the sheath of the guide catheter, said sheath having a deflection of at least 200 mm when a transverse force of 1N is applied to one end, with the other end rigidly fixed.

Classes IPC  ?

• A61B 8/12 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores dans des cavités ou des conduits du corps, p. ex. en utilisant des cathéters
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
• A61B 8/08 - Applications cliniques

Abrégé

The invention relates to an in vitro method for determining whether a sample contains a replicating virus, said method comprising detecting Papain-like protease activity (PLpro) of the virus.

Classes IPC  ?

• C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées

Abrégé

An in vitro or ex vivo method for determining the ability of an individual to respond to a stimulus, based on the measurement of the expression of at least two different biomarkers, selected from different lists among three lists of biomarkers, from a blood sample of the individual, incubated with the stimulus, as well as tools allowing the implementation of this method and the use of these tools.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12Q 1/6813 - Tests d’hybridation
• C12Q 1/6844 - Réactions d’amplification d’acides nucléiques

Abrégé

The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07D 235/18 - BenzimidazolesBenzimidazoles hydrogénés avec des radicaux aryle liés directement en position 2
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

The invention relates to a system and a method for computer-aided detection (CAD) of aggressive prostate cancers. The automatic diagnosis of aggressive prostate cancers is difficult and methods that work with some MRI scanners do not work as well when implemented on images from different scanners. By studying a data base containing MRI data and biopsy results from 265 patients, acquired by 4 different types of MRI scanners, using machine learning techniques, the inventors established a method for automatically determining the presence of aggressive cancers, this methods showing high sensitivity and specificity when implemented on another database containing MRI data from 270 patients, acquired by different MRI scanners than the first database. The method involves feeding MRI images to a system calculating a score for a portion of the prostate and determines that the portion contains an aggressive cancer based on whether a criterion depending on the score is verified.

Classes IPC  ?

• G06T 7/00 - Analyse d'image

Abrégé

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Classes IPC  ?

• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 31/215 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques
• A61K 31/665 - Composés du phosphore ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. fosfomycine
• A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
• A61K 31/13 - Amines, p. ex. amantadine
• A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim

Abrégé

A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
• C12Q 1/686 - Réaction en chaine par polymérase [PCR]

Abrégé

The invention relates to a process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

In the present invention, inventors investigate the representation of T cell subsets in Toxic epidermal necrolysis (TEN) a life-threatening cutaneous adverse drug reaction (cADR), characterized by massive epidermal necrosis. To better understand why skin symptoms are so severe in TEN disease, inventors conducted a prospective immunophenotyping study on skin samples and blood from 18 TEN patients, using mass cytometry and next generation TCR sequencing. Deep sequencing of the T cell receptor CDR3 repertoire revealed massive expansion of unique CDR3 clonotypes in blister cells. Over-represented clonotypes were mainly effector memory CD8+CD45RA-CCR7- T cells, and expressed high levels of cytotoxic (Granulysin and Granzymes A & B) and activation (CD38) markers. Thus present invention relates to non-invasive, specific and rapid methods for diagnostic and monitoring Toxic Epidermal Necrolysis. More specifically present invention relates to methods for diagnosis and/or monitoring of Toxic Epidermal Necrolysis through detection of a specific population of T ymphocytes in a subject. The present invention also relates to a method of preventing or treating a Toxic Epidermal Necrolysis in a subject in need thereof.

Classes IPC  ?

• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

Classes IPC  ?

• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 49/12 - Composés macromoléculaires
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
• A61P 35/00 - Agents anticancéreux

Abrégé

The present disclosure relates to nanoparticles and the uses thereof in medicine, in particular for the treatment of tumours.

Classes IPC  ?

• A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 49/12 - Composés macromoléculaires
• A61P 35/00 - Agents anticancéreux
• A61K 49/18 - Préparations de contraste pour la résonance magnétique nucléaire [RMN]Préparations de contraste pour l'imagerie par résonance magnétique [IRM] caractérisées par un aspect physique particulier, p. ex. émulsions, microcapsules, liposomes
• B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules

Abrégé

in vitroex vivomonophosphoryl lipid Amonophosphoryl lipid A (MPLA) or a derivative of MPLA, and then the expression of at least one biomarker is measured in said blood sample.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to a method for detecting an infectious transmission in a population, the method being characterised in that it comprises implementing, by data processing means (20) of a client (2), steps of: (b) for a plurality of infectious agent isolates, each associated with an individual of said population, obtaining a vector with values descriptive of the isolate; (c) for each pair of a first isolate (X) and a second isolate (Y) of the plurality, respectively associated with a first individual and a second individual of said population: (c1) calculating a first number of isolates (n(X)) corresponding to the number of isolates of said plurality having a distance to the first isolate (X) less than or equal to a reference distance between the first and second isolates (X, Y), and a second number of isolates (n(Y)) corresponding to the number of isolates of said plurality having a distance to the second isolate (Y) less than or equal to said reference distance between the first and second isolates (X, Y), each distance between two isolates being representative of a dissimilarity between the vectors of values descriptive of these two isolates; (c2) estimating a probability (TXY) of direct infectious transmission between the first and second individuals as a function of said first and second number of isolates (n(X), n(Y)); (d) detecting or not detecting an infectious transmission in said population as a function of the estimated probabilities (TXY) of direct infectious transition between each pair of individuals.

Classes IPC  ?

• G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
• G16B 20/40 - Génétique de populationDéséquilibre de liaison

Abrégé

The present invention relates to a method for detecting an infectious transmission in a population, the method being characterised in that it comprises implementing, by data processing means (20) of a client (2), steps of: (b) for a plurality of infectious agent isolates, each associated with an individual of said population, obtaining a vector with values descriptive of the isolate; (c) for each pair of a first isolate (X) and a second isolate (Y) of the plurality, respectively associated with a first individual and a second individual of said population: (c1) calculating a first number of isolates (n(X)) corresponding to the number of isolates of said plurality having a distance to the first isolate (X) less than or equal to a reference distance between the first and second isolates (X, Y), and a second number of isolates (n(Y)) corresponding to the number of isolates of said plurality having a distance to the second isolate (Y) less than or equal to said reference distance between the first and second isolates (X, Y), each distance between two isolates being representative of a dissimilarity between the vectors of values descriptive of these two isolates; (c2) estimating a probability (TXY) of direct infectious transmission between the first and second individuals as a function of said first and second number of isolates (n(X), n(Y)); (d) detecting or not detecting an infectious transmission in said population as a function of the estimated probabilities (TXY) of direct infectious transition between each pair of individuals.

Classes IPC  ?

• G16B 20/40 - Génétique de populationDéséquilibre de liaison
• G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe

Abrégé

The subject matter of the invention is a method for determining the proliferative capacity of T lymphocytes in a subject, the method comprising the following steps: a) measuring the load of torque teno virus from a biological sample of the subject; and b) determining the proliferative capacity of the T lymphocytes based on the viral load measured in a).

Classes IPC  ?

• C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
• C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages

Abrégé

The invention relates to an in vitro process for classifying a glioma, comprising the following steps: a. Measuring at least, from a glioma patient biological sample, the Alternative Lengthening of Telomeres (ALT) status of said glioma; b. Optionally, determining the isocitrate dehydrogenase genes mutation status (IDH status) of said glioma; c. Based on the data obtained in steps (a) and optionally (b) and, if available, on the histological grade of said glioma, classifying said glioma in one of the five following classes: oligodendroglioma-like, glioblastoma IDHwt-like, glioblastoma IDHmt-like, low-grade astrocytoma-like, and other gliomas.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to a cap for a biological sample collection device, the device comprising a collection receptacle (1) and a swab (2) for collecting a biological sample, the cap (3) comprising: - a cover (31) for capping the receptacle (1) - an internal element (32) projecting from the cover (31) and comprising at least first and second complementary clamping members (321, 322), the application of a pinch force to the cap (3) causing the free ends of the first and second clamping members (321, 322) to move towards each other.

Classes IPC  ?

• A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
• A61B 10/02 - Instruments pour prélever des échantillons cellulaires ou pour la biopsie

Abrégé

The invention relates to a process for identifying patients affected by an autoimmune neurological disease, comprising a step of detection of at least one type of anti-Argonaute autoantibodies (AGO-Abs) in a biological sample of an individual susceptible to be affected by said disease, wherein positive detection of said at least one type of AGO-Abs means that said individual is affected by said autoimmune neurological disease.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The invention relates to a process for identifying patients affected by an autoimmune neurological disease, comprising a step of detection of at least one type of anti-Argonaute autoantibodies (AGO-Abs) in a biological sample of an individual susceptible to be affected by said disease, wherein positive detection of said at least one type of AGO-Abs means that said individual is affected by said autoimmune neurological disease.

Classes IPC  ?

• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The invention relates to an imageable and resorbable medical device comprising at least one tubular portion (1) formed of a physical hydrogel of polysaccharides, capable of being inserted into the urethra of a subject, for various medical and/or surgical applications.

Classes IPC  ?

• A61L 29/04 - Matériaux macromoléculaires
• A61L 29/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
• A61L 31/04 - Matériaux macromoléculaires
• A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CD177 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CIITA in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to an avian model enabling the amplification of human or animal circulating tumour cells (CTC) and to the use thereof for monitoring and determining the sensitivity of a patient or an animal suffering from cancer to one or more therapeutic agent(s), as well as for screening novel therapeutic agents intended for the treatment of cancer.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• C12N 5/09 - Cellules tumorales

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of TAP2 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of C3AR1 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to an in vitro or ex vivo method for determining the risk of a care-related infection in a patient, comprising a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor, located in the region 2q11-2q12 of chromosome 2 in a biological sample of said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

A system for determining a pulse velocity wave comprises an interface for receiving a signal indicating the proximal blood pressure in an artery and for receiving a signal indicating distal blood pressure in the artery. A processing device is configured to determine a proximal rising edge between a diastolic pressure and the systolic pressure of the proximal signal; determine a proximal pressure peak prior to the proximal rising edge; determine a distal rising edge between a diastolic pressure and a systolic pressure of the distal signal; determine a distal pressure peak prior to the distal rising edge and to determine whether the distal pressure peak is in phase advance with respect to the proximal pressure peak; and determine a propagation velocity of a regressive pulse wave depending on the phase advance of the distal pressure peak.

Classes IPC  ?

• A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
• A61B 5/318 - Modalités électriques se rapportant au cœur, p. ex. électrocardiographie [ECG]
• A61B 5/339 - Affichages spécialement adaptés à cet effet
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/0215 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par des moyens introduits dans le corps

Abrégé

The present invention relates to an in vitro or ex vivo method based on the measurement of the expression of cytokine(s) from a blood sample of a patient, incubated with a stimulus, for determining the risk of incidence of a care-associated infection in the patient within a period of seven days from the day the blood sample was taken from the patient.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07D 235/18 - BenzimidazolesBenzimidazoles hydrogénés avec des radicaux aryle liés directement en position 2
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

The present invention relates to a vascularised cardiac organoid model comprising cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CM) grafted onto a chorioallantoic membrane of a fertilised egg. The present invention also relates to a method for obtaining the vascularised cardiac organoid model. The present intention also relates to a method for characterising the activity of a compound relative to the vascularised cardiac organoid model. The present invention also relates to a kit comprising the vascularised cardiac organoid model.

Classes IPC  ?

• C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
• C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains

Abrégé

The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.

Classes IPC  ?

• A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

Abrégé

The present invention concerns an in vitro or ex vivo method for determining an individual's ability to respond to a stimulus, based on the measurement of the expression of at least two different biomarkers, chosen from different lists among three lists of biomarkers, from a blood sample of the individual, incubated with the stimulus, and tools allowing this method to be implemented and the use of these tools.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates a fluorescent compound of formula I: wherein A is selected from P, P=O and N; • R1is a residue comprising an oxygen atom • R2is a residue comprising an oxygen atom, or a halogen, • R3, R4and R5 are alkyls, possibly substituted • or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.

Classes IPC  ?

• C09B 57/00 - Autres colorants synthétiques de structure connue
• G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
• A61K 49/00 - Préparations pour examen in vivo
• G01N 21/64 - FluorescencePhosphorescence
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

in vitroex vivoex vivo method for determining the risk of incidence of a care-associated infection in a patient, involving a step of measuring the expression of CX3CR1 in a biological sample from said patient.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The present invention relates to a non-implantable medical device (1, 1′) intended to cover wounds and skin lesions, comprising a biosensor (3E, 3E′), characterised in that said biosensor (3E, 3E′) comprises a piece made of absorbent, hydrophilic material fixing, on the surface and/or within the thickness thereof, a composition of agglomerated powders comprising particles of ethylene vinyl acetate (EVA) having a surface in part covered with at least one orthophosphoric acid salt and a visual indicator of microbiological growth. The present invention relates to a non-implantable medical device (1, 1′) intended to cover wounds and skin lesions, comprising a biosensor (3E, 3E′), characterised in that said biosensor (3E, 3E′) comprises a piece made of absorbent, hydrophilic material fixing, on the surface and/or within the thickness thereof, a composition of agglomerated powders comprising particles of ethylene vinyl acetate (EVA) having a surface in part covered with at least one orthophosphoric acid salt and a visual indicator of microbiological growth. In particular, the medical device (1, 1′) may comprise several layers in order to enable the guiding of a liquid. The present invention relates to a non-implantable medical device (1, 1′) intended to cover wounds and skin lesions, comprising a biosensor (3E, 3E′), characterised in that said biosensor (3E, 3E′) comprises a piece made of absorbent, hydrophilic material fixing, on the surface and/or within the thickness thereof, a composition of agglomerated powders comprising particles of ethylene vinyl acetate (EVA) having a surface in part covered with at least one orthophosphoric acid salt and a visual indicator of microbiological growth. In particular, the medical device (1, 1′) may comprise several layers in order to enable the guiding of a liquid. The present invention relates to a method for preparing such a medical device (1, 1′).

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61F 13/00 - Bandages ou pansementsGarnitures absorbantes
• A61L 15/24 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carboneLeurs dérivés
• A61L 15/18 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des matériaux inorganiques
• A61F 13/02 - Bandages ou pansements adhésifs
• A61K 49/00 - Préparations pour examen in vivo
• C12Q 1/14 - StreptocoquesStaphylocoques

Abrégé

vitrovitro process for classifying a glioma, comprising the following steps: a. Measuring at least, from a glioma patient biological sample, the Alternative Lengthening of Telomeres (ALT) status of said glioma; b. Optionally, determining the isocitrate dehydrogenase genes mutation status(IDH status) of said glioma; c. Based on the data obtained insteps(a)and optionally (b) and, if available, on the histological grade of said glioma, classifying said glioma in one of the five following classes: oligodendroglioma -like, glioblastoma IDHwt - like, glioblastoma IDHmt -like, low-grade astrocytoma -like, and other gliomas.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates to a method for diagnosing anomalies in the coagulation of blood, comprising the following successive steps: a) placing a sample of total blood in a holder containing two pairs of electrodes connected to an apparatus generating an electrical current; b) incubating this sample for 60 to 180 seconds in the presence of calcium; c) adding to this sample tissue factor in a concentration high enough to trigger the coagulation of the blood; d) measuring the impedance variation between the electrodes as a function of time, for a period comprised between 10 and 30 minutes from step (c), and generating a curve of the impedance values as a function of time; e) comparing the value of the area under the curve generated in step (d) with the value of an area under a reference curve.

Classes IPC  ?

• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
• G01N 27/07 - Structure des récipients de mesureÉlectrodes pour ces récipients

Abrégé

An apparatus for determining coronary pulse wave velocity uses proximal and distal pressure sensors that are separated by a known distance to collect waveforms with rising and falling edges and to use times between those edges together with the known distance to determine coronary pulse wave velocity.

Classes IPC  ?

• A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
• A61B 5/0215 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par des moyens introduits dans le corps
• G08B 21/02 - Alarmes pour assurer la sécurité des personnes

Abrégé

The invention relates to a system for determining a pulse velocity wave, comprising: - an interface (41) for receiving a signal indicating the proximal blood pressure in an artery (12, 13, 14, 15) and the receiving a signal indicating distal blood pressure; - a processing device (42) configured to: - determining a proximal rising edge between a diastolic pressure and the systolic pressure of the proximal signal; - determining a proximal pressure peak prior to said proximal rising edge; - determining a distal rising edge between a diastolic pressure and a systolic pressure of the distal signal; - determining a distal pressure peak prior to said distal rising edge, and determining whether the distal pressure peak is in phase advance with respect to the proximal pressure peak; - determining a propagation velocity of a regressive pulse wave depending on the phase advance of the distal pressure peak.

Classes IPC  ?

• A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
• A61B 5/0215 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par des moyens introduits dans le corps
• A61B 5/0285 - Mesure de la vitesse de propagation de l'onde pulsatile

Abrégé

The invention relates to a system for determining a pulse velocity wave, comprising: - an interface (41) for receiving a signal indicating the proximal blood pressure in an artery (12, 13, 14, 15) and the receiving a signal indicating distal blood pressure; - a processing device (42) configured to: - determining a proximal rising edge between a diastolic pressure and the systolic pressure of the proximal signal; - determining a proximal pressure peak prior to said proximal rising edge; - determining a distal rising edge between a diastolic pressure and a systolic pressure of the distal signal; - determining a distal pressure peak prior to said distal rising edge, and determining whether the distal pressure peak is in phase advance with respect to the proximal pressure peak; - determining a propagation velocity of a regressive pulse wave depending on the phase advance of the distal pressure peak.

Classes IPC  ?

• A61B 5/021 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/0456 - Détection des crêtes de l'onde R, p.ex. pour la synchronisation d'appareils de diagnostic
• A61B 5/0452 - Détection de paramètres spécifiques du cycle de l'électrocardiogramme
• A61B 5/0285 - Mesure de la vitesse de propagation de l'onde pulsatile
• A61B 5/02 - Détection, mesure ou enregistrement en vue de l'évaluation du système cardio-vasculaire, p. ex. mesure du pouls, du rythme cardiaque, de la pression sanguine ou du débit sanguin
• A61B 5/0215 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par des moyens introduits dans le corps

Abrégé

The present invention relates to an avian model for the amplification of human or animal circulating tumor cells (CTCs) and to the use thereof for follow-up and for determining the sensitivity of a cancer patient or animal to one or more therapeutic agents, as well as for screening novel therapeutic agents for the treatment of cancer.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• C12N 5/09 - Cellules tumorales
• C12N 5/095 - Cellules souchesCellules progénitrices
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to an avian model for the amplification of human or animal circulating tumor cells (CTCs) and to the use thereof for follow-up and for determining the sensitivity of a cancer patient or animal to one or more therapeutic agents, as well as for screening novel therapeutic agents for the treatment of cancer.

Classes IPC  ?

• A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
• C12N 5/095 - Cellules souchesCellules progénitrices
• C12N 5/09 - Cellules tumorales
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a method for determining in vitro or ex vivo the immune status of an individual, preferably a patient, comprising a step of detecting and/or quantifying the expression of one or more HERV/MaLR sequences in a biological sample of said individual. The invention also relates to the tools for implementing said method and to the uses thereof.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

Osteoarthritis (OA) is the most frequent chronic musculoskeletal disease affecting approximately 40% of adults aged 70 years and over. The inventors investigated the associations of prevalent and incident knee osteoarthritis (OA) with the expression levels of serum miRs in subjects with and without OA. By real-time PCR, they analyzed the expression levels of 19 miRs at baseline selecting 43 women with prevalent OA (Kellgren Lawrence score of 2/3), 23 women with incident OA over a 4 years follow-up and 67 healthy subjects without prevalent or incident OA matched for age and body mass index. miR-146a-5p was significantly increased in the group of prevalent OA compared with controls (RQ: relative quantification; median [Interquartile range]: 1.12 [0.73; 1.46] vs 0.85 [0.62; 1.03], p=0.015). The likelihood of prevalent OA was significantly increased (odds-ratio [95% confidence interval (CI)]: 1.83 [1.21-2.77], p=0.004) for each quartile increase in serum miR-146a-5p. There was a significant association between baseline miR-186 levels and the risk of incident OA (Q4 vs Q1-3; odds- ratio [95% CI]: 6.13 [1.14-32.9], p=0.034). In conclusion the inventors showed for the first time that miR-146a-5p and miR-186 are significantly associated with prevalent and incident OA respectively.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention relates to a process in vitro for diagnosing a paraneoplastic neurological syndrome (PNS) associated with a tumor in an individual, comprising the detection of at least one antibody chosen among antibodies against TRIM9 and antibodies against TRIM67, in a biological fluid of said individual.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

12312311).

Classes IPC  ?

• G01T 1/20 - Mesure de l'intensité de radiation avec des détecteurs à scintillation

Abrégé

The invention concerns a device (100) for assisting a practitioner in adjusting the length of artificial chordae implanted in an heart valve, the device (100) comprising a plurality of gripping elements (41-44), each gripping element (41-44) handling an end of a respective artificial chordae extending outward from the patient so that the device (100) remains outside from the patient, wherein the device (100) further comprises a plurality of force sensors (31-34), each force sensor being fixed to a respective gripping element (41-44) for measuring a signal representative of a tension of the chordae hold by the gripping element (41-44) associated to the force sensor.

Classes IPC  ?

• A61F 2/24 - Valvules de cœur

Abrégé

The invention relates to a non-implantable medical device (1, 1') designed to cover wounds and skin lesions, which has a biosensor (3E, 3E'), characterised in that said biosensor (3E, 3E') comprises a piece of absorbent, hydrophilic material on which, on the surface and/or within the thickness thereof, a composition of agglomerated powders is immobilised, said composition comprising ethylene vinyl acetate (EVA) particles, the surfaces of which are partially coated with at least one salt of orthophosphoric acid and a visual indicator of microbiological growth. In particular, the medical device (1, 1') can have multiple layers to allow a liquid to be guided. The invention relates to a method for preparing a medical device of this type (1, 1').

Classes IPC  ?

• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12Q 1/14 - StreptocoquesStaphylocoques

Abrégé

The present invention relates to an in vitro method for evaluating the prognosis of an autoimmune or chronic inflammatory disease in an individual, comprising the following steps: a) determining (i) the level of an anti-IL-17 autoantibody and/or (ii) the level of an [IL-17/anti-IL-17 autoantibody] complex in a biological sample of the individual, and b) comparing the level of autoantibody and/or of complex determined in step a) with a reference value, the comparison being indicative of the prognosis of an autoimmune or chronic inflammatory disease in said individual.

Classes IPC  ?

• G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The present invention relates to a pharmaceutical combination product comprising: - a liposomal formulation containing exclusively an LPS; and - at least one cytotoxic compound. The invention also relates to the use thereof in anti-tumour therapy.

Classes IPC  ?

• A61K 35/74 - Bactéries
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 31/7024 - Esters de saccharides
• A61P 35/00 - Agents anticancéreux
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

in vitroin vitro process for determining the prognosis of a primary breast cancer tumor in a patient, comprising the following steps: a) Assessing the level of expression of BCL-2 L10 protein in a sample of said breast cancer tumor from said patient; b) Comparing said level of expression with at least one reference value chosen among (i) a value representative of "BCL-2 L10 negative tumors", (ii) a value representative of "BCL-2 L10 positive tumors" and (iii) a cut-off value; c) Identifying said tumor as being "BCL-2 L10 negative" or "BCL-2 L10 positive", wherein if said tumor is identified in step (c) as being BCL2-L10 positive, said patient is classified as presenting a shorter distant metastasis free survival (DMFS).

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

in vivoin vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 38/00 - Préparations médicinales contenant des peptides

Abrégé

The invention relates to an in vitro method for predicting the risk for transplant rejection in a transplanted subject. The inventors have shown that innate immune effectors NK cells could trigger microvascular inflammation and chronic transplant rejection. NK-mediated rejection was due to the lack of expression by the graft of at least one type of HLA-I ligand for an inhibitory KIR expressed by recipient NK cells Thus the invention relates to an in vitro method for predicting the risk of transplant rejection in a transplanted subject comprising the detection of missing-self activation of NK cells. The inventors also showed that m TOR inhibitors are efficient to prevent missing-self mediated transplant rejection. The invention thus relates to an m Tor inhibitor for use in the prevention or treatment of a transplanted recipient subject at risk of missing-self mediated transplant rejection.

Classes IPC  ?

• C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique

Abrégé

The present invention relates to a non-invasive, specific and rapid diagnostic method of Familial Mediterranean fever (FMF) in a subject said method comprising the step of measuring the level of cytokine (IL-18 or IL-1 beta) secreted by immune primary cells (or cell death level of these cells) obtained from said subject, which have been beforehand treated with a Protein Kinase C (PKC) inhibitor, and optionally beforehand treated with a NF-kB activator such as LPS. Inventors show based on the extensive study of the inflammasome process of the monocytes, that PKC superfamily inhibitors trigger inflammasome activation in monocytes from FMF patients while they are not sufficient to do so in monocytes from healthy donors (HD) or from patient having hyperimmunoglobulinemia D syndrome (HIDS). Using cytokine release quantification or determination of real time cell death kinetics, inventors demonstrate that PKC superfamily inhibitors can discriminate FMF patients from HD or from patients with systemic inflammation from other aetiologies. These results thus set-up the basis for the development of a rapid functional specific diagnostic test for FMF. Methods of treatment are disclosed.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes

Abrégé

The present invention concerns an inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus. Inventors show that the knock-down of histone chaperone HIRA before HBV inoculation led to a strong decrease in HBV cccDNA (covalently closed circular DNA) accumulation and stable rcDNA (relaxed circular DNA) levels, in HepG2-NTCP cell line, indicating either a possible incomplete or delayed rcDNA to cccDNA transition. This effect was independent from HBx protein expression in Primary human hepatocytes (PHH). HIRA is able to interact with cccDNA and its recruitment is concomitant with deposition of histone variant H3.3 in HepG2-NTCP cell line. HIRA was able to interact with HBc (HBV capsid protein) in infected hepatocytes and in an HepaRG cell line expressing HBc in an inducible manner.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens